Viet Nam

Tuberculosis profile

Population 2018: 96 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>174 (111–251)</td>
<td>182 (116–263)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>6 (3.8–8.6)</td>
<td>6.2 (4–9)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>8.6 (5.4–13)</td>
<td>9.1 (5.7–13)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>11 (6.7–15)</td>
<td>11 (7–16)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.2 (1.4–3.2)</td>
<td>2.3 (1.5–3.4)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases: 3.6% (3.4–3.8)
Previously treated cases: 17% (17–18)

TB case notifications, 2018

Total new and relapse: 99,658
- % tested with rapid diagnostics at time of diagnosis: 20%
- % with known HIV status: 85%
- % pulmonary: 80%
- % bacteriologically confirmed: 70%
- % children aged 0–14 years: 2%
- % women: 27%
- % men: 71%

Total cases notified: 102,171

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018: 57% (40–90)
TB patients facing catastrophic total costs, 2016: 63% (58–67)
TB case fatality ratio (estimated mortality/estimated incidence), 2018: 8% (4–12)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive
- on antiretroviral therapy: 2,902 (3%)
- 2,705 (93%)

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance:
- New cases: 82%
- Previously treated cases: 100%

Laboratory-confirmed cases:
MDR/RR-TB: 3,126, XDR-TB: 61

Patients started on treatment:
MDR/RR-TB: 3,110, XDR-TB: 198
MDR/RR-TB cases tested for resistance to second-line drugs: 1,922

Tuberculosis preventive strategy, 2018

% of HIV-positive people (newly enrolled in care) on preventative treatment: 39%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventative treatment: 22% (21–25)

TB financing, 2019

National TB budget (US$ millions): 72

<table>
<thead>
<tr>
<th>Treatment success rate and cohort size</th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2017</td>
<td>92%</td>
<td>102,193</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2017</td>
<td>87%</td>
<td>2,983</td>
</tr>
<tr>
<td>HIV-positive TB cases registered in 2017</td>
<td>79%</td>
<td>3,002</td>
</tr>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2016</td>
<td>68%</td>
<td>2,450</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2016</td>
<td>68%</td>
<td>28</td>
</tr>
</tbody>
</table>

Unfunded, Funded internationally, Funded domestically

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-15

Data: www.who.int/tb/data